NEUTROPHIL COUNT DECREASED and RIBASPHEREPatientsVille
NEUTROPHIL COUNT DECREASED Symptoms and Causes
We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.
Check out the latest treatments for NEUTROPHIL COUNT DECREASED
Find Drug Side Effect reports
Marax was the asthma the best medicine for me to treat asthma. Inhalers do not work. Apparently centuries of using the contents of Marax with success does not count with the FDA. Shame on them. Bring back this medication.
I just started taking lisinopril and am also staying very tired. Dizziness and lightheadness are my biggest problems right now.I am taking this with cardura and zoloft, so it may not count here. But i wanted to share my input and after reading the c
had my first shot of aranesp one week ago for anemia , i have renal failure, I'm 62 , and I am a working nurse. I will be getting aranesp every 2 weeks if my blood count is less than 11. well out of no where I have becom
1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy & apprehensive' but better than the alternative
After a urinalisis the doctor told me there were no white blood cells, only red blood cells in urine. drew blood and had cat scan and revealed a 7mm kidney stone. but i'm worried about having no white blood cell count in my urine
NEUTROPHIL COUNT DECREASED Clinical Trials and StudiesTreatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Ribavirin Pre-treatment Followed by Combined Standard Therapy in Hepatitis C Virus (HCV) Recipients
Tailored Regimens of PEGASYS® and Ribavirin for Genotype 1 Chronic Hepatitis C Patients Trial (TARGET-1)
In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia
RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin
Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)
Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
Miravirsen in Combination With Telaprevir and Ribavirin in Null Responder to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Infection
|10||Not yet recruiting||
A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD)
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection
Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Four Arms, Multicenter Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C
A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus
Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma
Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve Sustained Virologic Response (SVR) in Genotype 2, 3 Chronic Hepatitis C Patients?
An Open Label Trial of Pegylated Interferon, Ribavirin and Telaprevir Versus Pegylated Interferon and Ribavirin Alone in the Treatment of Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection
Interferon and Ribavirin Treatment in Patients With Hemoglobinopathies
Phase IV Study to Evaluate the Efficacy/Safety to Extend Treatment and High Dose of Ribavirin in co-Infected Patients